Complementary and alternative medicine in inflammatory bowel disease: keeping an open mind

References

• Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV. Trichuris suis therapy in Crohn’s disease. Gut 54, 87–90 (2005).
   PubMed Web of Science ®Google Scholar
• Summers RW, Elliott DE, Urban JF Jr, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128, 825–832 (2005).
   PubMed Web of Science ®Google Scholar
• Elliott DE, Summers RW, Weinstock JV. Helminths and the modulation of mucosal inflammation. Curr. Opin. Gastroenterol. 21, 51–58 (2005).
   PubMed Web of Science ®Google Scholar
• Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280, 1569–1575 (1998).
   PubMed Web of Science ®Google Scholar
• Thomas KJ, Nicholl JP, Coleman P. Use and expenditure on complementary medicine in England: a population based survey. Complement. Ther. Med. 9, 2–11 (2001).
   PubMed Web of Science ®Google Scholar
• Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv. Data 1–19 (2004).
   Google Scholar
• Monti DA, Yang J. Complementary medicine in chronic cancer care. Semin. Oncol. 32, 225–231 (2005).
   PubMed Web of Science ®Google Scholar
• George J, Ioannides-Demos LL, Santamaria NM, Kong DC, Stewart K. Use of complementary and alternative medicines by patients with chronic obstructive pulmonary disease. Med. J. Aust. 181, 248–251 (2004).
   PubMed Web of Science ®Google Scholar
• Braganza S, Ozuah PO, Sharif I. The use of complementary therapies in inner-city asthmatic children. J. Asthma 40, 823–827 (2003).
   PubMed Web of Science ®Google Scholar
• Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch. Intern. Med. 163, 265–274 (2003).
   PubMed Web of Science ®Google Scholar
• Day AS, Whitten KE, Bohane TD. Use of complementary and alternative medicines by children and adolescents with inflammatory bowel disease. J. Paediatr. Child. Health 40, 681–684 (2004).
   PubMed Web of Science ®Google Scholar
• Heuschkel R, Afzal N, Wuerth A et al. Complementary medicine use in children and young adults with inflammatory bowel disease. Am. J. Gastroenterol. 97, 382–388 (2002).
   PubMed Web of Science ®Google Scholar
• Markowitz JE, Mamula P, delRosario JF et al. Patterns of complementary and alternative medicine use in a population of pediatric patients with inflammatory bowel disease. Inflamm. Bowel Dis. 10, 599–605 (2004).
   Google Scholar
• Otley AR, Verhoef MJ, Best A, Hilsden RJ. Prevalence and determinants of use of complementary and alternative medicine in a Canadian pediatric inflammatory bowel disease population. Gastroenterology 120, A213 (2001).
   Google Scholar
• Elson CO, Sartor RB, Targan SR, Sandborn WJ. Challenges in IBD research: updating the scientific agendas. Inflamm. Bowel Dis. 9, 137–153 (2003).
   PubMed Web of Science ®Google Scholar
• Holloway H, Mullen W, Fielding JF. Who best assesses Crohn’s disease? Ir. J. Med. Sci. 165, 95–98 (1996).
   Google Scholar
• Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol. Clin. North Am. 28, 445–458 (1999).
   PubMed Web of Science ®Google Scholar
• Oliva-Hemker M, Fiocchi C. Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm. Bowel Dis. 8, 112–128 (2002).
   PubMed Web of Science ®Google Scholar
• Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn’s disease. Gut 34, 939–943 (1993).
   PubMed Web of Science ®Google Scholar
• Hyams JS, Davis P, Grancher K, Lerer T, Justinich CJ, Markowitz J. Clinical outcome of ulcerative colitis in children. J. Pediatr. 129, 81–88 (1996).
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Krasilnikoff PA, Binder V. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand. J. Gastroenterol. 32, 139–147 (1997).
   PubMed Web of Science ®Google Scholar
• Ferguson A, Sedgwick DM, Drummond J. Morbidity of Juvenile Onset Inflammatory Bowel Disease: Effects on Education and Employment in Early Adult Life. Gut 35, 665–668 (1994).
   PubMed Web of Science ®Google Scholar
• Gryboski J. Ulcerative Colitis in Children 10 Years or younger. J. Pediatr. Gastroenterol. Nutr. 17, 24–31 (1993).
   PubMed Web of Science ®Google Scholar
• Gryboski JD. Crohn’s Disease in Children 10 Years Old and younger: Comparison with Ulcerative Colitis. J. Pediatr. Gastroenterol. Nutr. 18, 174–182 (1994).
   PubMed Web of Science ®Google Scholar
• Barton JR, Gillon S, Ferguson A. Incidence of Inflammatory Bowel Disease in Scottish Children between 1968 and 1983; Marginal Fall in Ulcerative Colitis, Three-Fold Rise in Crohn’s Disease. Gut 30, 618–622 (1989).
   PubMed Web of Science ®Google Scholar
• Mir-Madjlessi SH, Michener WM, Farmer RG. Course and Prognosis of Idiopathic Ulcerative Proctosigmoiditis in Young Patients. J. Pediatr. Gastroenterol. Nutr. 5, 570–575 (1986).
   Web of Science ®Google Scholar
• Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 18, 165–173 (1994).
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 16, 373–380 (1993).
   PubMed Web of Science ®Google Scholar
• Savage MO, Beattie RM, Camacho-Hubner C, Walker-Smith JA, Sanderson IR. Growth in Crohn’s disease. Acta Paediatr. Suppl. 428, 89–92 (1999).
   Google Scholar
• Saha M-T, Ruuska T, Laippala P, Lenko HL. Growth of Prepubertal Children with Inflammatory Bowel Disease. J. Pediatr. Gastroenterol. Nutr. 26, 310–314 (1998).
   PubMedGoogle Scholar
• Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EOB. Growth Failure in Children with Inflammatory Bowel Disease: A Prospective Study. Gastroenterology 105, 681–691 (1993).
   PubMed Web of Science ®Google Scholar
• Nicholls S, Vieira MC, Majrowski WH, Shand WS, Savage MO, Walker-Smith JA. Linear Growth After Colectomy for Ulcerative Colitis in Childhood. J. Pediatr. Gastroenterol. Nutr. 21, 82–86 (1995).
   PubMedGoogle Scholar
• Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol. Clin. North Am. 32, 967–995, (2003).
   PubMed Web of Science ®Google Scholar
• Griffiths AM. Inflammatory bowel disease. Adolesc. Med. 6, 351–368 (1995).
   Google Scholar
• Sherman PM, Griffiths A, Marcon M, Smith C, Geist R. Lifestyle issues in children and adolescents with chronic inflammatory bowel diseases. Can. J. Gastroenterol. 4, 364–368 (1990).
   Google Scholar
• Griffiths AM. Inflammatory bowel disease. Nutrition 14, 788–791 (1998).
   PubMed Web of Science ®Google Scholar
• Kemper KJ, Cassileth B, Ferris T. Holistic pediatrics: a research agenda. Pediatrics 103, 902–909 (1999).
   Google Scholar
• Caspi O, Sechrest L, Pitluk HC, Marshall CL, Bell IR, Nichter M. On the definition of complementary, alternative, and integrative medicine: societal mega-stereotypes vs. the patients’ perspectives. Altern. Ther. Health Med. 9, 58–62 (2003).
   PubMedGoogle Scholar
• Eisenberg DM, Kessler RC, Van Rompay MI et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann. Intern. Med. 135, 344–351 (2001).
   PubMed Web of Science ®Google Scholar
• Defining and describing complementary and alternative medicine. Panel on Definition and Description, CAM Research Methodology Conference, April 1995. Altern. Ther. Health Med. 3, 49–57 (1997).
   Google Scholar
• Druss BG, Rosenheck RA. Association between use of unconventional therapies and conventional medical services. JAMA 282, 651–656 (1999).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Davis RB, Foster DF et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann. Intern. Med. 135, 262–268 (2001).
   PubMed Web of Science ®Google Scholar
• Hilsden RJ, Scott CM, Verhoef MJ. Complementary medicine use by patients with inflammatory bowel disease. Am. J. Gastroenterol. 93, 697–701 (1998).
   PubMed Web of Science ®Google Scholar
• Hilsden RJ, Dunn C, Patten S, Scott CM, Verhoef MJ. Information needs and seeking behaviors of patients with inflammatory bowel disease. Gastroenterology 114, A995 (1998).
   Google Scholar
• Spigelblatt L, Laine-Ammara G, Pless IB, Guyver A. The use of alternative medicine by children. Pediatrics 94, 811–814 (1994).
   PubMed Web of Science ®Google Scholar
• Ottolini MC, Hamburger EK, Loprieato JO et al. Complementary and alternative medicine use among children in the Washington, DC area. Ambul. Pediatr. 1, 122–125 (2001).
   PubMedGoogle Scholar
• Madsen H, Andersen S, Nielsen RG, Dolmer BS, Host A, Damkier A. Use of complementary/alternative medicine among paediatric patients. Eur. J. Pediatr. 162, 334–341 (2003).
   PubMed Web of Science ®Google Scholar
• Simpson N, Roman K. Complementary medicine use in children: extent and reasons. A population-based study. Br. J. Gen. Pract. 51, 914–916 (2001).
   PubMed Web of Science ®Google Scholar
• Rawsthorne P, Shanahan F, Cronin NC et al. An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. Am. J. Gastroenterol. 94, 1298–1303 (1999).
   PubMed Web of Science ®Google Scholar
• Wasner CK. The art of unproven remedies. Rheum. Dis. Clin. North Am. 17, 197–202 (1991).
   Google Scholar
• Hilsden RJ, Meddings JB, Verhoef MJ. Complementary and alternative medicine use by patients with inflammatory bowel disease: An internet survey. Can. J. Gastroenterol. 13, 327–332 (1999).
   PubMed Web of Science ®Google Scholar
• Quattropani C, Ausfeld B, Straumann A, Heer P, Seibold F. Complementary alternative medicine in patients with inflammatory bowel disease: use and attitudes. Scand. J. Gastroenterol. 38, 277–282 (2003).
   PubMed Web of Science ®Google Scholar
• Moody GA, Eaden JA, Bhakta P, Sher K, Mayberry JF. The role of complementary medicine in European and Asian patients with inflammatory bowel disease. Public Health 112, 269–271 (1998).
   PubMed Web of Science ®Google Scholar
• Fioramonti J, Theodorou V, Bueno L. Probiotics: what are they? What are their effects on gut physiology? Best Pract. Res. Clin. Gastroenterol. 17, 711–724 (2003).
   PubMed Web of Science ®Google Scholar
• Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126, 1620–1633 (2004).
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Madsen KL. Probiotics and prebiotics in gastrointestinal disorders. Curr. Opin. Gastroenterol. 20, 146–155 (2004).
   PubMed Web of Science ®Google Scholar
• Marteau P, Seksik P, Shanahan F. Manipulation of the bacterial flora in inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. 17, 47–61 (2003).
   PubMed Web of Science ®Google Scholar
• Tamboli CP, Caucheteux C, Cortot A, Colombel JF, Desreumaux P. Probiotics in inflammatory bowel disease: a critical review. Best Pract. Res. Clin. Gastroenterol. 17, 805–820 (2003).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119, 305–309 (2000).
   PubMed Web of Science ®Google Scholar
• Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL #3) for maintaining remission in recurrent or refractory pouchitis. Gut 53, 108–114 (2004).
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J. Am. Coll. Nutr. 22, 56–63 (2003).
   PubMed Web of Science ®Google Scholar
• Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 11, 853–858 (1997).
   PubMed Web of Science ®Google Scholar
• Kruis W, Fric P, Stolte M. Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology 120, A127 (2001).
   Google Scholar
• Gupta P, Andrew H, Kirschner BS, Guandalini S. Is Lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study. J. Pediatr. Gastroenterol. Nutr. 31, 453–457 (2000).
   PubMed Web of Science ®Google Scholar
• McCarthy J, O’Mahony L, Dunne C. An open trial of a novel probiotic as an alternative to steroids in mild/moderately active Crohn’s disease. Gut 49, 2447 (2001).
   Google Scholar
• Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig. Dis. Sci. 45, 1462–1464 (2000).
   PubMed Web of Science ®Google Scholar
• Malchow HA. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J. Clin. Gastroenterol. 25, 653–658 (1997).
   PubMed Web of Science ®Google Scholar
• Campieri M, Rizzello F, Venturi A et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn’s disease: a randomized controlled study vs. mesalamine. Gastroenterology 118, A781 (2000).
   Web of Science ®Google Scholar
• Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut 51, 405–409 (2002).
   PubMed Web of Science ®Google Scholar
• Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J. Clin. Gastroenterol. 37, 42–47 (2003).
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Gionchetti P, Campieri M et al. VSL3 Probiotic Mixture Induces Remission in Patients with Active Ulcerative Colitis. Gastroenterology 124, A377 (2003).
   Google Scholar
• Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354, 635–639 (1999).
   PubMed Web of Science ®Google Scholar
• Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 15, 697–698 (2003).
   Google Scholar
• Kanauchi O, Mitsuyama K, Homma T et al. Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int. J. Mol. Med. 12, 701–704 (2003).
   PubMed Web of Science ®Google Scholar
• Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Am. J. Gastroenterol. 94, 427–433 (1999).
   PubMed Web of Science ®Google Scholar
• Hanai H, Kanauchi O, Mitsuyama K et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int. J. Mol. Med. 13, 643–647 (2004).
   PubMed Web of Science ®Google Scholar
• Kanauchi O, Matsumoto Y, Matsumura M, Fukuoka M, Bamba T. The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease. Curr. Pharm. Des. 11, 1047–1053 (2005).
   PubMed Web of Science ®Google Scholar
• Furrie E, Macfarlane S, Kennedy A et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54, 242–249 (2005).
   PubMed Web of Science ®Google Scholar
• Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J. Pediatr. Gastroenterol. Nutr. 31, 8–15 (2000).
   PubMed Web of Science ®Google Scholar
• Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn’s disease. Cochrane Database Syst. Rev. CD000542 (2001).
   Google Scholar
• Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology 108, 1056–1067 (1995).
   PubMed Web of Science ®Google Scholar
• Fernandez-Banares F, Cabre E, Esteve-Comas M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn’s disease? A meta-analysis of the randomized clinical trials. JPEN J. Parenter. Enteral. Nutr. 19, 356–364 (1995).
   PubMed Web of Science ®Google Scholar
• Sanderson IR, Naik S. Dietary regulation of intestinal gene expression. Ann. Rev. Nutr. 20, 311–338 (2000).
   Google Scholar
• Vernia P, Annese V, Bresci G et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur. J. Clin. Invest. 33, 244–248 (2003).
   PubMed Web of Science ®Google Scholar
• Steinhart AH, Hiruki T, Brzezinski A, Baker JP. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment. Pharmacol. Ther. 10, 729–736 (1996).
   PubMed Web of Science ®Google Scholar
• Breuer RI, Soergel KH, Lashner BA et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo-controlled trial. Gut 40, 485–491 (1997).
   PubMed Web of Science ®Google Scholar
• Shoda R, Matsueda K, Yamato S, Umeda N. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am. J. Clin. Nutr. 63, 741–745 (1996).
   PubMed Web of Science ®Google Scholar
• Alzoghaibi MA, Walsh SW, Willey A, Yager DR, Fowler AA III, Graham MF. Linoleic acid induces interleukin-8 production by Crohn’s human intestinal smooth muscle cells via arachidonic acid metabolites. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G528–G537 (2004).
   Web of Science ®Google Scholar
• Head K, Jurenka JS. Inflammatory bowel disease. Part II: Crohn’s disease-pathophysiology and conventional and alternative treatment options. Altern. Med. Rev. 9, 360–401 (2004).
   PubMedGoogle Scholar
• Salomon P, Kornbluth AA, Janowitz HD. Treatment of ulcerative colitis with fish oil n-3-omega-fatty acid: an open trial. J. Clin. Gastroenterol. 12, 157–161 (1990).
   PubMed Web of Science ®Google Scholar
• McCall TB, O’Leary D, Bloomfield J, O’Morain CA. Therapeutic potential of fish oil in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 3, 415–424 (1989).
   PubMed Web of Science ®Google Scholar
• Lorenz R, Weber PC, Szimnau P, Heldwein W, Strasser T, Loeschke K. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease-a randomized, placebo-controlled, double-blind cross-over trial. J. Intern. Med. Suppl. 731, 225–232 (1989).
   PubMedGoogle Scholar
• Hawthorne AB, Daneshmend TK, Hawkey CJ et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 33, 922–928 (1992).
   PubMed Web of Science ®Google Scholar
• Stenson WF, Cort D, Rodgers J et al. Dietary supplementation with fish oil in ulcerative colitis. Ann. Intern. Med. 116, 609–614 (1992).
   PubMed Web of Science ®Google Scholar
• Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am. J. Gastroenterol. 87, 432–437 (1992).
   PubMed Web of Science ®Google Scholar
• Lorenz-Meyer H, Bauer P, Nicolay C et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn’s disease. A randomized controlled multicenter trial. Study Group Members (German Crohn’s Disease Study Group). Scand. J. Gastroenterol. 31, 778–785 (1996).
   PubMed Web of Science ®Google Scholar
• Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N. Engl. J. Med. 334, 1557–1560 (1996).
   PubMed Web of Science ®Google Scholar
• Belluzzi A, Boschi S, Brignola C, Munarini A, Cariani G, Miglio F. Polyunsaturated fatty acids and inflammatory bowel disease. Am. J. Clin. Nutr. 71, S339–S342 (2000).
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Miller V, Stanton J, Elbadri AM, Thomas AG. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn’s disease. J. Pediatr. Gastroenterol. Nutr. 30, 78–84 (2000).
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Miller V, Thomas AG, Richmond K. Glutamine supplementation and intestinal permeability in Crohn’s disease. JPEN J. Parenter. Enteral. Nutr. 24, 196 (2000).
   Google Scholar
• Den Hond E, Hiele M, Peeters M, Ghoos Y, Rutgeerts P. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn’s disease. JPEN J. Parenter. Enteral. Nutr. 23, 7–11 (1999).
   PubMedGoogle Scholar
• Goodman MJ, Kent PW, Truelove SC. Glucosamine synthetase activity of the colonic mucosa in ulcerative colitis and Crohn’s disease. Gut 18, 219–228 (1977).
   PubMed Web of Science ®Google Scholar
• Salvatore S, Heuschkel R, Tomlin S et al. A pilot study of N-acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in paediatric chronic inflammatory bowel disease. Aliment. Pharmacol. Ther. 14, 1567–1579 (2000).
   PubMed Web of Science ®Google Scholar
• Gottschall E. In: Breaking the Vicious Cycle: Intestinal Health Through Diet. Kirkton Press, ON, USA (1994).
   Google Scholar
• Heaton KW, Thornton JR, Emmett PM. Treatment of Crohn’s disease with an unrefined-carbohydrate, fibre-rich diet. Br. Med. J. 2, 764–766 (1979).
   PubMed Web of Science ®Google Scholar
• Jones VA, Dickinson RJ, Workman E, Wilson AJ, Freeman AH, Hunter JO. Crohn’s disease: maintenance of remission by diet. Lancet 2, 177–180 (1985).
   PubMed Web of Science ®Google Scholar
• Ritchie JK, Wadsworth J, Lennard-Jones JE, Rogers E. Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn’s disease. Br. Med. J. (Clin. Res. Ed.) 295, 517–520 (1987).
   Google Scholar
• Simpson N, Pearce A, Finlay F, Lenton S. The use of complementary medicine in paediatric out-patient clinics. Ambul. Child Health 3, 351–356 (1998).
   Google Scholar
• Kiela PR, Midura AJ, Kuscuoglu N et al. Effects of Boswellia serrata in mouse models of chemically induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G798–G808 (2005).
   PubMed Web of Science ®Google Scholar
• Canadian Pediatric Society, DTaHSC. Children and natural health products: what a clinician should know. Paediatrics Child Health 10, 227–232 (2005).
   Google Scholar
• Perharic L, Shaw D, Colbridge M, House I, Leon C, Murray V. Toxicological problems resulting from exposure to traditional remedies and food supplements. Drug Saf. 11, 284–294 (1994).
   PubMed Web of Science ®Google Scholar
• Feldstein TJ. Carbohydrate and alcohol content of 200 oral liquid medications for use in patients receiving ketogenic diets. Pediatrics 97, 506–511 (1996).
   Google Scholar
• Cui J, Garle M, Eneroth P, Bjorkhem I. What do commercial ginseng preparations contain? Lancet 344, 134 (1994).
   PubMed Web of Science ®Google Scholar
• Langmead L, Dawson C, Hawkins C, Banna N, Loo S, Rampton DS. Anti-oxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment. Pharmacol. Ther. 16, 197–205 (2002).
   PubMed Web of Science ®Google Scholar
• Hodge G, Hodge S, Han P. Allium sativum (garlic) suppresses leukocyte inflammatory cytokine production in vitro: potential therapeutic use in the treatment of inflammatory bowel disease. Cytometry 48, 209–215 (2002).
   PubMedGoogle Scholar
• Aggarwal BB, Shishodia S. Suppression of the nuclear factor-{kappa}B activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. NY Acad. Sci. 1030, 434–441 (2004).
   PubMed Web of Science ®Google Scholar
• Kane S, Goldberg MJ. Use of bromelain for mild ulcerative colitis. Ann. Intern. Med. 132, 680 (2000).
   PubMed Web of Science ®Google Scholar
• Sandberg-Gertzen H. An open trial of Cedemin, a Gingko biloba extract with PAF-antagonistic effects for ulcerative colitis. Am. J. Gastroenterol. 88, 615–616 (1993).
   Google Scholar
• Etienne A, Thonier F, Braquet P. Protective effect of the PAF-antagonist BN 52021 on several models of gastro-intestinal mucosal damage in rats. Int. J. Tissue React. 11, 59–64 (1989).
   Google Scholar
• Krieglstein CF, Anthoni C, Rijcken EJ et al. Acetyl-11-keto-β-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int. J. Colorectal. Dis. 16, 88–95 (2001).
   PubMed Web of Science ®Google Scholar
• Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R. Therapy of active Crohn disease with Boswellia serrata extract H15. Z. Gastroenterol. 39, 11–17 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta I, Parihar A, Malhotra P et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med. 67, 391–395 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta I, Parihar A, Malhotra P et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur. J. Med. Res. 2, 37–43 (1997).
   PubMedGoogle Scholar
• Pugh N, Ross SA, ElSohly MA, Pasco DS. Characterization of Aloeride, a new high-molecular-weight polysaccharide from Aloe vera with potent immunostimulatory activity. J. Agric. Food Chem. 49, 1030–1034 (2001).
   PubMed Web of Science ®Google Scholar
• Eshun K, He Q. Aloe vera: a valuable ingredient for the food, pharmaceutical and cosmetic industries-a review. Crit. Rev. Food Sci. Nutr. 44, 91–96 (2004).
   PubMed Web of Science ®Google Scholar
• Langmead L, Chitnis M, Rampton DS. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm. Bowel Dis. 8, 174–179 (2002).
   PubMed Web of Science ®Google Scholar
• Langmead L, Feakins RM, Goldthorpe S et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment. Pharmacol. Ther. 19, 739–747 (2004).
   PubMed Web of Science ®Google Scholar
• Chen Z. Treatment of ulcerative colitis with acupuncture. J. Tradit. Chin. Med. 15, 231–233 (1995).
   PubMedGoogle Scholar
• Zhang SL, You SZ. A clinical summary on 61 cases of chronic colitis treated by laser acupuncture. Zhen Ci Yan Jiu12, 180–181 (1987).
   Google Scholar
• Zhang X. 23 cases of chronic nonspecific ulcerative colitis treated by acupuncture and moxibustion. J. Tradit. Chin. Med. 18, 188–191 (1998).
   PubMedGoogle Scholar
• Joos S, Brinkhaus B, Maluche C et al. Acupuncture and moxibustion in the treatment of active Crohn’s disease: a randomized controlled study. Digestion 69, 131–139 (2004).
   PubMed Web of Science ®Google Scholar
• Wu HG, Zhou LB, Pan YY et al. Study of the mechanisms of acupuncture and moxibustion treatment for ulcerative colitis rats in view of the gene expression of cytokines. World J. Gastroenterol. 5, 515–517 (1999).
   PubMed Web of Science ®Google Scholar
• Wu HG, Gong X, Yao LQ et al. Mechanisms of acupuncture and moxibustion in regulation of epithelial cell apoptosis in rat ulcerative colitis. World J. Gastroenterol. 10, 682–688 (2004).
   PubMed Web of Science ®Google Scholar
• Zijlstra FJ, van den Berg-de Lange I, Huygen FJ, Klein J. Anti-inflammatory actions of acupuncture. Mediators Inflamm. 12, 59–69 (2003).
   PubMed Web of Science ®Google Scholar
• Maunder R. Mediators of stress effects in inflammatory bowel disease: not the usual suspects. J. Psychosom. Res. 48, 569–577 (2000).
   Google Scholar
• Collins SM. Stress and the gastrointestinal tract IV. Modulation of intestinal inflammation by stress: basic mechanisms and clinical relevance. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G315–G318 (2001).
   PubMed Web of Science ®Google Scholar
• Qiu BS, Vallance BA, Blennerhassett PA, Collins SM. The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis. Nature Med. 5, 1178–1182 (1999).
   PubMed Web of Science ®Google Scholar
• Kiliaan AJ, Saunders PR, Bijlsma PB et al. Stress stimulates transepithelial macromolecular uptake in rat jejunum. Am. J. Physiol. 275, G1037–G1044 (1998).
   PubMed Web of Science ®Google Scholar
• Milne B, Joachim G, Niedhardt J. A stress Management Programme for Inflammatory Bowel Disease Patients. J. Adv. Nurs. 11, 561–567 (1986).
   PubMed Web of Science ®Google Scholar
• Schwarz SP, Blanchard EB. Evaluation of a psychological treatment for inflammatory bowel disease. Behav. Res. Ther. 29, 167–177 (1991).
   PubMed Web of Science ®Google Scholar
• Keller W, Pritsch M, Von Wietersheim J et al. Effect of psychotherapy and relaxation on the psychosocial and somatic course of Crohn’s disease: main results of the German Prospective Multicenter Psychotherapy Treatment study on Crohn’s Disease. J. Psychosom. Res. 56, 687–696 (2004).
   PubMed Web of Science ®Google Scholar
• Hilsden RJ, Verhoef MJ, Best A, Pocobelli G. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am. J. Gastroenterol. 98, 1563–1568 (2003).
   PubMed Web of Science ®Google Scholar